Abstract: Disclosed are a microgranular water-soluble fertilizer co-produced from potassium nitrate by tower melt and a method of preparing the same, which relate to the technical field of production of water-soluble fertilizers. The microgranular water-soluble fertilizer co-produced from potassium nitrate by tower melt is prepared from potassium nitrate concentrate, urea, industrial monoammonium phosphate, water-soluble ammonium polyphosphate, potassium sulfate, EDTA-Fe, EDTA-Zn, EDTA-Mn, boric acid and ammonium heptamolybdate. The microgranular water-soluble fertilizer product co-produced from potassium nitrate by tower melt has balanced and stable nutrients. The product is microgranular, has a smooth appearance, is less susceptible to agglomeration, is easy to be absorbed and utilized by crops, and contains a full range of nutrients. In addition, the product is produced by a process employing fully automatic dispensing equipment, which mainly integrates “dispensing, mixing and packaging” and is fully automated.

Abstract: Provided are methods and systems for determining score consistency.

Abstract: Provided are methods and systems for determining score consistency.

Abstract: The present invention relates to the inclusion complexes of butylphthalide, which is D, L-mixed or levorotatory, with cyclodextrin or cyclodextrin derivatives, to a process for their preparation and the use thereof. In the invention, the butylphthalide is complexed with cyclodextrin or cyclodextrin derivatives, preferably with hydroxypropyl-?-cyclodextrin in order to increase the water-solubility of butylphthalide, develop clinical solid or liquid formulations and improve the therapeutic effect of butylphthalide. The inclusion complex, in which the molar ratio of butylphthalide to cyclodextrin or cyclodextrin derivatives is in the range of 1:1-10, can be used to prepare infusion, injection, injectable powder, liquids for oral administration, syrup, tablets, granules, dispersible tablets and others.

Abstract: Provided are methods and systems for determining score consistency.

Abstract: The present invention relates to the inclusion complexes of butylphthalide, which is D, L-mixed or levorotatory, with cyclodextrin or cyclodextrin derivatives, to a process for their preparation and the use thereof. In the invention, the butylphthalide is complexed with cyclodextrin or cyclodextrin derivatives, preferably with hydroxypropyl-?-cyclodextrin in order to increase the water-solubility of butylphthalide, develop clinical solid or liquid formulations and improve the therapeutic effect of butylphthalide. The inclusion complex, in which the molar ratio of butylphthalide to cyclodextrin or cyclodextrin derivatives is in the range of 1:1-10, can be used to prepare infusion, injection, injectable powder, liquids for oral administration, syrup, tablets, granules, dispersible tablets and others.

Abstract: The present invention relates to the inclusion complexes of butylphthalide, which is D,L-mixed or levorotatory, with cyclodextrin or cyclodextrin derivatives, to a process for their preparation and the use thereof. In the invention, the butylphthalide is complexed with cyclodextrin or cyclodextrin derivatives, preferably with hydroxypropyl-?-cyclodextrin, in order to increase the water-solubility of butylphthalide, develop clinical solid or liquid formulations and improve the therapeutic effect of butylphthalide. The inclusion complex, in which the molar ratio of butylphthalide to cyclodextrin or cyclodextrin derivatives is in the range of 1:1-10, can be used to prepare infusion, injection, injectable powder, liquids for oral administration, syrup, tablets, granules, dispersible tablets and others.

Abstract: A method and apparatus to determine an optimum collimator angle of a multi-leaf collimator having an opening and multiple leaf pairs for closing portions of the opening to form a radiation beam arrangement having multiple radiation beam segments. The method and apparatus include application of a cost function to determine a collimator angle which provides for delivery efficiency and target conformity. The user can preferentially either selectively enhance delivery efficiency of the radiation beam arrangement, reducing a number of radiation beam segments and reducing a number of radiation beam monitor units required for delivery of the desired prescription, or selectively enhance conformity of the radiation beam arrangement to a target shape. The optimum collimator angle is then used for delivery of an optimized radiation beam arrangement to a patient by a radiation delivery device.